**Tirzepatide**, sold under the brand name Mounjaro, is a medication used for the treatment of type 2 diabetes. Tirzepatide is given by subcutaneous injection (under the skin). Common side effects may include nausea, vomiting, diarrhea, constipation, upper abdominal discomfort, and abdominal pain. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar control. Tirzepatide is a first-in-class medication that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control. Tirzepatide was approved for medical use in the United States in May 2022. Developed by [[Eli Lilly]]. Source: [Wikipedia](https://en.wikipedia.org/wiki/Tirzepatide)